49c Medi+Sure® Glucose Test Strips now approved to BC PharmaCare.

AJAX, ON, Aug. 27, 2012 /CNW/ - Medi+Sure Canada is a Canadian company dedicated to delivering high quality and affordable medical products to the Canadian diabetic healthcare market.

Medi+Sure Canada is pleased to advise that the Government of British Columbia has now approved its 49c Medi+Sure® Blood Glucose Test Strips to BC's PharmaCare Benefit Program.

Effective August 15th 2012 Medi+Sure Glucose Test Strips were approved and are now eligible in BC for full PharmaCare coverage as a regular benefit.

In July 2012, Manitoba was first to approve 49c Medi+Sure Glucose Test Strips to its Provincial Healthcare Drug Reimbursement Formulary.

According to Mario Cortis the President and Spokesperson for MediSure Canada Inc:
"BC is the 2nd province in the past 2 months to approve our safe, reliable and affordable Medi+Sure Blood Glucose Strips for provincial insurance coverage. We are delighted with this latest announcement and proud to help Canadian's to reduce healthcare costs. At 49 cents per strip, MediSure brings previously unattainable savings to B.C. Diabetics and their Government, as all other glucose test strip brands cost about 33% more".

According to the Canadian Diabetes Association, over 3 million Canadians are Diabetic and each spends on average $2000 in out of pocket expenses to manage this disease. In most provinces in Canada Provincial Governments pay about 73 cents per glucose test strip, about twice the amount that USA Medicare pays for its glucose strips.

Medi+Sure™® Blood Glucose products are Health Canada Licensed, safe, reliable, high quality and affordable products that save Provincial Governments and taxpayer's money.

SOURCE MediSure Canada Inc

Suggested Articles

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.

AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.